umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Correlation of molecular subtypes with overall survival (OS) in AVAglio, a randomized, placebo-controlled study of bevacizumab (BEV) plus radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GBM)
Show others and affiliations
2014 (English)In: Neuro-Oncology, ISSN 1522-8517, E-ISSN 1523-5866, Vol. 16, no 5Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
2014. Vol. 16, no 5
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-101428DOI: 10.1093/neuonc/nou239.22ISI: 000350452200112OAI: oai:DiVA.org:umu-101428DiVA: diva2:800182
Available from: 2015-04-02 Created: 2015-03-30 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Henriksson, Roger
By organisation
Oncology
In the same journal
Neuro-Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 77 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf